AZD2858

AZD2858 是具有口服活性的GSK-3抑制剂,可以抑制 GSK-3α (IC50:0.9 nM) 和 GSK-3β (IC50:5 nM) 的活性,可用于骨折愈合的研究。

CAS号

486424-20-8

分子式

C21H23N7O3S

主要靶点

GSK-3

仅限科研使用

Cat No : CM04322

Print datasheet

Synonyms



产品信息

AZD2858 is a selective GSK-3 inhibitor, inhibiting tau phosphorylation at the S396 site and activating Wnt signaling pathway.

CAS号 486424-20-8
分子式 C21H23N7O3S
主要靶点 GSK-3
主要通路 PI3K/Akt/mTOR信号通路|干细胞
分子量 453.52
纯度 99.25%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名

靶点活性

GSK-3:68 nM

体内活性

AZD2858在人类和大鼠间充质干细胞中引起β-连环蛋白稳定,激活体外成骨细胞和成骨矿化。初级分离的人成骨细胞样细胞上AZD2858处理(1 μM,12小时)导致β-连环蛋白水平增加3倍。

体外活性

30 μM/kg AZD2858处理大鼠三周后胼胝中矿物质密度(2周时28%,三周时38%)和矿物质含量(两周时81%,三周时93%)增加.大鼠用AZD2858处理28天后,血清中骨更新标志物产生时间依赖性变化,且骨密度增加.大鼠用AZD2858处理7天后,骨形成标志P1NP增加,溶蚀标志物TRAcP-5b降低,表明骨合成代谢增加,大鼠吸收减少.大鼠口服AZD2858治疗两周后,与对照组相比,引起骨密度剂量依赖增加,治疗两周后,在每天20 mg/kg(总BMC: 对照组的172%)剂量下具有最大疗效.AZD2858处理使骨折恢复更快,有骨性骨痂但没有明显的软骨成分.

溶解度

Ethanol:<1 mg/mL,DMSO:7 mg/mL (15.43 mM)

细胞实验

Human adipose derived stem cells and rat MSCs (isolated from bone marrow of Sprague Dawley rats at less than 8 weeks after gestation) are cultured in a basal media of DMEM containing 5% FBS and 2 mM GlutaMax. Cells are seeded in basal media into 96-well plates (3–5000 cells/well) for 18 h before treatment with AZD2858 (0.3 nM to 20 mM). After 24 h, β-catenin stabilisation is measured.(Only for Reference)

参考文献

1.Marsell R, et al. Bone, 2012, 50(3), 619-627.
2.Gilmour PS, Toxicol Appl Pharmacol, 2013, 272(2), 399-407.
3.Sisask G, et al. Bone, 2013, 54(1), 126-132.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2